StockNews.com Downgrades Adverum Biotechnologies to Sell - MarketBeat

ADVM Stock  USD 4.40  0.07  1.62%   
About 52% of Adverum Biotechnologies' investor base is interested to short. The analysis of the overall investor sentiment regarding Adverum Biotechnologies suggests that many traders are impartial. Adverum Biotechnologies' investing sentiment overview a quick insight into current market opportunities from investing in Adverum Biotechnologies. Many technical investors use Adverum Biotechnologies stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
StockNews.com Downgrades Adverum Biotechnologies to Sell MarketBeat

Read at news.google.com
Google News at Macroaxis
  

Adverum Biotechnologies Fundamental Analysis

We analyze Adverum Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adverum Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adverum Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Adverum Biotechnologies is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Adverum Biotechnologies Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adverum Biotechnologies stock to make a market-neutral strategy. Peer analysis of Adverum Biotechnologies could also be used in its relative valuation, which is a method of valuing Adverum Biotechnologies by comparing valuation metrics with similar companies.

Peers

Adverum Biotechnologies Related Equities

AFMDAffimed NV   6.48   
0%
100.0%
AVTEAerovate Therapeutics   6.17   
0%
95.0%
QUREUniqure NV   6.12   
0%
94.0%
MGTXMeiraGTx Holdings   5.56   
0%
85.0%
RYTMRhythm Pharmaceuticals   5.46   
0%
84.0%
ACRVAcrivon Therapeutics,   4.14   
0%
63.0%
ABSIAbsci Corp   3.57   
0%
55.0%
PASGPassage Bio   3.33   
0%
51.0%
RZLTRezolute   2.31   
0%
35.0%
KZRKezar Life   2.26   
0%
34.0%
ANTXAN2 Therapeutics   1.60   
0%
24.0%
RCKTRocket Pharmaceuticals   0.98   
0%
15.0%
SLDBSolid Biosciences   0.31   
4.0%
0%
ADAGAdagene   0.54   
8.0%
0%
GLMDGalmed Pharmaceuticals   1.02   
15.0%
0%
STOKStoke Therapeutics   1.06   
16.0%
0%
MREOMereo BioPharma   1.38   
21.0%
0%
KODKodiak Sciences   6.15   
94.0%
0%
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out Adverum Biotechnologies Hype Analysis, Adverum Biotechnologies Correlation and Adverum Biotechnologies Performance.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.